NEW YORK – Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company focusing on oncology with a market capitalization of $902 million, announced the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for taletrectinib, a treatment for advanced ROS1-positive non-small cell lung cancer (NSCLC). The FDA has granted Priority Review and set a Prescription Drug User Fee Act (PDUFA) goal date of June 23, 2025. According to InvestingPro data, the company’s stock has delivered an impressive 79.87% return over the past year, reflecting growing investor confidence in its pipeline.
Taletrectinib is a next-generation ROS1 tyrosine kinase inhibitor (TKI) designed to treat patients with advanced ROS1+ NSCLC. The NDA submission is supported by data from the TRUST-I and TRUST-II Phase 2 studies, which demonstrated durable responses and prolonged progression-free survival in patients. InvestingPro analysis shows the company maintains a strong financial position with a current ratio of 9.57, indicating robust liquidity to support its drug development programs. Analyst price targets range from $5 to $8, suggesting significant upside potential from current levels.
David Hung, M.D., CEO of Nuvation Bio, expressed optimism about the drug’s potential, citing that taletrectinib is backed by data from over 300 patients, representing the largest dataset for an original NDA in this patient population. Dr. Hung also noted that taletrectinib has previously received Orphan Drug Designation and is the only ROS1 TKI with Breakthrough Therapy Designation from the FDA for the treatment of locally advanced or metastatic ROS1+ NSCLC, regardless of prior ROS1 TKI treatment.
The pivotal pooled data from the TRUST-I and TRUST-II studies, presented at the European Society of Medical (TASE:) Oncology (ESMO) Congress in September 2024, includes results from 337 patients with advanced ROS1+ NSCLC. The primary endpoint of the studies is the confirmed objective response rate (cORR), with key secondary endpoints including intracranial cORR, duration of response (DOR), progression-free survival (PFS), and safety.
ROS1+ NSCLC is a subset of lung cancer with a global incidence rate of more than one million diagnoses annually, with approximately 2% of NSCLC patients having ROS1+ disease. The need for effective and tolerable treatments is underscored by the high percentage of patients with brain metastases at diagnosis and progression. While currently pre-revenue with negative earnings, InvestingPro data reveals the company holds more cash than debt, positioning it well to advance its therapeutic pipeline. For detailed financial analysis and additional insights, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
Nuvation Bio, founded in 2018, is developing a portfolio of novel oncology therapeutics, including taletrectinib. The company has offices in New York, San Francisco, Boston, and Shanghai. The acceptance of the NDA for taletrectinib is based on a press release statement from Nuvation Bio.
In other recent news, Nuvation Bio Inc. has been the subject of significant developments. Clear Street recently initiated coverage on Nuvation Bio with a Buy rating and a $5.00 price target, based on the potential of the company’s drug, taletrectinib. The firm believes that this drug could outperform other agents in the market in terms of efficacy and safety, possibly leading to a robust growth trajectory for Nuvation Bio.
In addition to this, Nuvation Bio announced the appointment of Philippe Sauvage as its new Chief Financial Officer. Sauvage brings over two decades of experience in financial and operational leadership within the healthcare sector, which will be instrumental as the company transitions into a commercial-stage organization.
In financial news, Nuvation Bio reported a net loss of $0.07 per share for the first quarter of 2024, which was better than projected. The company maintains a robust cash position of $597 million, projected to fund operations through 2028.
In terms of leadership, David Hung, M.D., was appointed Chair of the Board, and Robert B. Bazemore, Jr. was appointed Lead Independent (LON:) Director. Lastly, both H.C. Wainwright and BTIG have maintained their Buy ratings on Nuvation Bio, reflecting their confidence in the company’s prospects. These are the recent developments that have been taking place at Nuvation Bio Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
